Substituted Alkyl Imidazolines Group
These substances were identified for action under the Chemicals Management Plan (CMP). The screening assessment focuses on 4 of 8 substances referred to collectively as the Substituted Alkyl Imidazolines Group.
|Substance Group||CAS RN||DSL name||Public comments on the draft screening assessment||Final screening assessment||Conclusion on section 64 criteria||Follow-up activities|
|Substituted Alkyl Imidazolines Group||95-38-5||1H-Imidazole-1-ethanol, 2-(8-heptadecenyl)-4,5-dihydro-||HTML||HTML||Does not meet||None planned at this time|
|68442-97-7Footnote 1,Footnote 2||1H-Imidazole-1-ethanamine, 4,5-dihydro-, 2-nortall-oil alkyl derivs.|
|December 26, 2020||Publication of the final screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 154, No. 52.|
|June 22, 2019||Publication and start of 60-day public comment period on the draft screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 153, No. 25.|
Four other substances were identified as being a part of the Alkyl Imidazolines and Salts Group at the outset of the third phase of the CMP. Two of these substances were subsequently determined to be of low concern to both human health and the environment, through other approaches. The conclusion for CAS RN 21652-27-7 is provided in the Final Screening Assessment of Substances Identified as Being of Low Concern using the Ecological Risk Classification of Organic Substances and the Threshold of Toxicological Concern (TTC)-based Approach for Certain Substances. The conclusion for CAS RN 31135-57-6 is provided in the Final Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure. CAS RNs 67633-57-2 and 68122-86-1 will be assessed in a future screening assessment.
Report a problem or mistake on this page
- Date modified: